Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash & Equivalents (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash & Equivalents for 9 consecutive years, with $70.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $70.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.1 million, a N/A change, with the full-year FY2025 number at $70.1 million, changed N/A from a year prior.
  • Cash & Equivalents was $70.1 million for Q4 2025 at Soleno Therapeutics, down from $246.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $246.7 million in Q3 2025 to a low of $70.1 million in Q4 2025.